Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study
- PMID: 32112737
- DOI: 10.1016/S1470-2045(20)30027-9
Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study
Abstract
Background: In patients with metastatic neuroendocrine neoplasms, the liver is the most commonly affected organ and a crucial factor for prognosis and survival. Peptide receptor radionuclide therapy can prolong progression-free survival in these patients. Additional treatment of liver disease might further improve outcomes. We aimed to investigate the safety and efficacy of additional holmium-166 (166Ho) radioembolisation after peptide receptor radionuclide therapy in patients with metastatic liver neuroendocrine neoplasms.
Methods: The Holmium Embolization Particles for Arterial Radiotherapy Plus 177Lu-Dotatate in Salvage Neuroendocrine Tumour Patients (HEPAR PLuS) study was a single-centre, phase 2 study done at the University Medical Center Utrecht (Utrecht, Netherlands). Patients, aged at least 18 years, with histologically proven grade 1 or 2 neuroendocrine neoplasms of all origins, an Eastern Cooperative Oncology Group performance status of 0-2, and three or more measurable liver metastases according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria received 166Ho-radioembolisation within 20 weeks after four cycles of peptide receptor radionuclide therapy (lutetium-177-dotatate [177Lu-dotatate]). The primary endpoint was objective liver tumour response in the treated liver volume, defined as complete response (disappearance of all lesions) or partial response (≥30% decrease in the sum of the longest diameters of the target lesions, compared with baseline measurements), according to RECIST 1.1, analysed per protocol at 3 months. Safety was assessed in all patients who received treatment. This study is registered with ClinicalTrials.gov, NCT02067988. Recruitment is completed and long-term follow-up is ongoing.
Findings: From Oct 15, 2014, to Sept 12, 2018, 34 patients were assessed for eligibility. 31 patients received treatment and 30 (97%) patients were available for primary endpoint assessment and completed 6 months of follow-up. Three (9%) patients were excluded at screening and one (3%) patient was treated and died before the primary endpoint and was replaced. According to the per-protocol analysis 13 (43%; 95% CI 26-63) of 30 patients achieved an objective response in the treated volume. The most frequently reported Common Terminology Criteria for Adverse Events (CTCAE) grade 3-4 clinical and laboratory toxicities within 6 months included abdominal pain (three [10%] of 31 patients), increased γ-glutamyl transpeptidase (16 [54%]), and lymphocytopenia (seven [23%]). One (3%) fatal treatment-related serious adverse event occurred (radioembolisation-induced liver disease). Two (6%) patients had serious adverse events deemed to be unrelated to treatment (gastric ulcer and perforated cholecystitis).
Interpretation: 166Ho-radioembolisation, as an adjunct to peptide receptor radionuclide therapy in patients with neuroendocrine neoplasm liver metastases, is safe and efficacious. Radioembolisation can be considered in patients with bulky liver disease, including after peptide receptor radionuclide therapy. A future randomised, controlled study should investigate the added benefit of this treatment on progression-free survival.
Funding: None.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Comment in
-
Holmium-166 radioembolisation after peptide receptor radionuclide therapy: much needed data to help inform future research.Lancet Oncol. 2020 Apr;21(4):478-479. doi: 10.1016/S1470-2045(20)30083-8. Epub 2020 Feb 26. Lancet Oncol. 2020. PMID: 32112735 No abstract available.
-
Combining radiolabelled therapies for neuroendocrine neoplasms.Nat Rev Endocrinol. 2020 Jul;16(7):347-348. doi: 10.1038/s41574-020-0367-3. Nat Rev Endocrinol. 2020. PMID: 32382045 No abstract available.
Similar articles
-
Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial).BMC Gastroenterol. 2018 Jun 15;18(1):84. doi: 10.1186/s12876-018-0817-8. BMC Gastroenterol. 2018. PMID: 29902988 Free PMC article. Clinical Trial.
-
Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study.Lancet Oncol. 2012 Oct;13(10):1025-34. doi: 10.1016/S1470-2045(12)70334-0. Epub 2012 Aug 22. Lancet Oncol. 2012. PMID: 22920685 Clinical Trial.
-
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15. Lancet Oncol. 2021. PMID: 34793718 Clinical Trial.
-
Radionuclide Therapy for Neuroendocrine Tumors.Curr Oncol Rep. 2017 Feb;19(2):9. doi: 10.1007/s11912-017-0567-8. Curr Oncol Rep. 2017. PMID: 28220446 Review.
-
Liver-Directed Therapies for Neuroendocrine Neoplasms.Curr Oncol Rep. 2021 Mar 15;23(4):44. doi: 10.1007/s11912-021-01030-0. Curr Oncol Rep. 2021. PMID: 33721122 Review.
Cited by
-
Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management.Curr Oncol. 2024 Apr 5;31(4):2076-2091. doi: 10.3390/curroncol31040154. Curr Oncol. 2024. PMID: 38668057 Free PMC article. Review.
-
Advances in Radionuclide Therapies for Patients with Neuro-endocrine Tumors.Curr Oncol Rep. 2024 May;26(5):551-561. doi: 10.1007/s11912-024-01521-w. Epub 2024 Apr 10. Curr Oncol Rep. 2024. PMID: 38598035 Free PMC article. Review.
-
Dose-effect relationships in neuroendocrine tumour liver metastases treated with [166Ho]-radioembolization.Eur J Nucl Med Mol Imaging. 2024 Jun;51(7):2114-2123. doi: 10.1007/s00259-024-06645-6. Epub 2024 Feb 19. Eur J Nucl Med Mol Imaging. 2024. PMID: 38369678 Free PMC article.
-
Lung Mean Dose Prediction in Transarterial Radioembolization (TARE): Superiority of [166Ho]-Scout Over [99mTc]MAA in a Prospective Cohort Study.Cardiovasc Intervent Radiol. 2024 Apr;47(4):443-450. doi: 10.1007/s00270-023-03656-y. Epub 2024 Feb 7. Cardiovasc Intervent Radiol. 2024. PMID: 38326577 Free PMC article.
-
Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA).Eur J Nucl Med Mol Imaging. 2024 Mar;51(4):1121-1132. doi: 10.1007/s00259-023-06467-y. Epub 2023 Oct 28. Eur J Nucl Med Mol Imaging. 2024. PMID: 37897617 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous